300871 回盛生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)10.539-1.3591.1003.3368.864
总资产报酬率 ROA (%)6.292-0.6730.5631.8395.913
投入资产回报率 ROIC (%)7.181-0.7760.6602.0906.510

边际利润分析
销售毛利率 (%)29.36716.33420.91622.03227.175
营业利润率 (%)17.194-2.4231.4795.78315.160
息税前利润/营业总收入 (%)17.8700.9593.6156.92214.701
净利润/营业总收入 (%)14.965-1.6471.6465.15313.337

收益指标分析
经营活动净收益/利润总额(%)89.870101.72527.630105.46988.995
价值变动净收益/利润总额(%)5.30753.335203.95212.3612.920
营业外收支净额/利润总额(%)-0.921-0.386-21.231-4.316-0.130

偿债能力分析
流动比率 (X)1.7051.4221.6211.6793.177
速动比率 (X)1.3631.1531.3281.4322.717
资产负债率 (%)28.39551.39849.27648.43240.954
带息债务/全部投入资本 (%)15.90442.45637.23236.72333.241
股东权益/带息债务 (%)514.336129.269159.755164.582195.408
股东权益/负债合计 (%)251.01894.069102.940106.476144.179
利息保障倍数 (X)21.4600.2841.5095.022-33.417

营运能力分析
应收账款周转天数 (天)81.441103.004115.881100.27678.329
存货周转天数 (天)76.27185.46595.45697.17489.025